Marine ω-3, vitamin D levels, disease outcome and periodontal status in rheumatoid arthritis outpatients
Peer reviewed, Journal article
MetadataShow full item record
Original versionBeyer K, Lie SA, Kjellevold MK, Dahl L, Brun JG, Bolstad AI. Marine ω-3, vitamin D levels, disease outcome and periodontal status in rheumatoid arthritis outpatients. Nutrition (Burbank, Los Angeles County, Calif.). 2018;55-56:116-124 https://doi.org/10.1016/j.nut.2018.03.054
Objectives: Marine ω-3 fatty acids (FAs) and Vitamin D (VitD) are reportedly capable of down-regulating inflammation in rheumatoid arthritis (RA) and periodontal disease. This study was undertaken to relate marine FA and VitD status to RA disease status and periodontal conditions. Methods: RA outpatients (age ≥35 y) were consecutively recruited. Rheumatologic clinical data were collected and periodontal status obtained. A food frequency questionnaire was used to estimate fish and supplement intake. FA profiles in whole-blood and serum VitD levels were determined. Results: A total of 78 RA patients (age 57 ± 12 y, disease duration 15 ± 11 y) were included, 58% had active RA. Periodontitis was diagnosed in 82% of the patients, 18% had severe periodontitis. Seropositivity for rheumatoid factor and/or anticitrullinated protein antibodies was related to higher prevalence of periodontitis (P = 0.008). Seafood intake in accordance with nutritional recommendations was associated with better RA disease outcome (largest P = 0.008). An ω-3 index >8, present in 14% of the patients, correlated with a more desirable patient global health assessment scored on a visual analog scale (VAS; P = 0.004), lower periodontal probing depth (PD; P = 0.021), and ω-3 supplementation (P = 0.001). Serum VitD levels >50 nmol/L were found in 89%, of these 48% had VitD levels ≥75 nmol/L, no differences were found for RA disease activity and periodontal measurements. Conclusions: Seropositive RA patients had a higher prevalence of periodontitis than seronegative patients. An ω-3 index >8 was related to ω-3 supplementation and more desirable VAS and lower PD. VitD status was satisfactory for most patients and was not associated with differences in RA severity or periodontal diagnosis.